2-氯-7-羧基苯并噻唑 | 1379324-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氯-7-羧基苯并噻唑
• 英文名称: 2-chlorobenzothiazole-7-carboxylic acid
• 英文别名: 2-Chlorobenzo[d]thiazole-7-carboxylic acid；2-chloro-1,3-benzothiazole-7-carboxylic acid
• CAS: 1379324-66-9
• 化学式: C₈H₄ClNO₂S
• 分子量: 213.644
• InChiKey: MMDQFYIMUCGXIW-UHFFFAOYSA-N

物化性质

• 沸点：
  398.2±15.0 °C(Predicted)
• 密度：
  1.634±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为产物：
  描述：

  2-chloro-7-benzothiazolecarboxylic acid ethyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以91 %的产率得到2-氯-7-羧基苯并噻唑
  参考文献：
  名称：

  Silver-Catalyzed Skeletal Editing of Benzothiazol-2(3H)-ones and 2-Halogen-Substituted Benzothiazoles as a Rapid Single-Step Approach to Benzo[1,2,3]thiadiazoles

  摘要：

  DOI：

  10.1021/acs.orglett.3c03904

文献信息

• Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same
  申请人：Yuhan Corporation

  公开号：US10383859B2

  公开（公告）日：2019-08-20

  The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  本发明提供了一种苯并[d]噻唑衍生物或其药学上可接受的盐、其制备工艺以及包含其的药物组合物。苯并[d]噻唑衍生物或其药学上可接受的盐可以选择性地抑制 KRS 与层粘连蛋白受体（LR）之间的蛋白-蛋白相互作用，从而抑制癌细胞的迁移。因此，苯并[d]噻唑衍生物或其药学上可接受的盐可用于预防或治疗与癌细胞转移相关的疾病。
• BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
  申请人：Yuhan Corporation

  公开号：EP3483149B1

  公开（公告）日：2021-01-13
• Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same
  申请人：Yuhan Corporation

  公开号：US20190142809A1

  公开（公告）日：2019-05-16

  The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.
• Silver-Catalyzed Skeletal Editing of Benzothiazol-2(3<i>H</i>)-ones and 2-Halogen-Substituted Benzothiazoles as a Rapid Single-Step Approach to Benzo[1,2,3]thiadiazoles
  作者：Jela Nociarová、Anisha Purkait、Róbert Gyepes、Peter Hrobárik

  DOI：10.1021/acs.orglett.3c03904

  日期：2024.1.26